National Drug Screening NDASA 2022

National Drug Screening’s (NDS) executive team is heading to Indianapolis May 4-6 to add our voice and industry authority to the National Drug and Alcohol Screening Association’s (NDASA) annual conference. We hope you’ll look for us at this national meeting of professionals working in the drug testing industry; workplace and public safety; and aspects of public health, corporate human resources and workforce development.

As one of fewer than 30 firms in the United States nationally accredited to administer drug and alcohol testing programs, NDS is a proud conference sponsor and a member of NDASA, a leading voice of the nation’s drug-testing industry. NDS regularly assists NDASA’s leadership team with consultation and resources to promote the organization’s mission to advocate “for safe and drug-free workplaces and communities through legislative advocacy, education, training and excellence in drug and alcohol screening services.” NDS also works to help NDASA members increase their market reach through our National Drug Screening Collection Site Network, which drives business to collectors for fixed facility collections and for onsite mobile collections and also provides them with resources to support their business development.

NDASA’s national conference will provide attendees three days of professional training, valuable insight from fantastic speakers and an array of business networking opportunities. Look for the NDS team in Exhibition Booth 12 at the conference’s trade show, which is expected to attract several hundred visitors. This year’s conference speakers include keynote speaker (Ret.) U.S. Army Gen. Barry McCaffrey, a former director of the White Office of National Drug Control Policy, and Dan Schneider, a grieving father and activist at the center of critically acclaimed Netflix docu-series “The Pharmacist.”

NDS invites you to learn more about the upcoming NDASA conference and to register today.

NDSA Logo

More Posts

FMCSA Post Accident Testing Guidelines

A. Certain employees are required to submit to post-accident urine drug testing as required by the US DOT and FMCSA guidelines. B. An employee will